or Try an Advanced Search...

    Glucagon Like Peptide 1 Stocks List

    Symbol Grade Name % Change
    VANI D Vivani Medical, Inc. 0.56
    NVO D Novo Nordisk A/S 1.25
    ORMP F Oramed Pharmaceuticals Inc. 5.96
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Diabetes Peptide Hormones Endocrine System Insulin Medicine Anti Diabetic Drugs Biopharmaceutical Chronic Disease Diabetes Care Gastrointestinal Growth Hormone Growth Hormone Therapy Haemophilia Hormone Therapy Hormones Implant Inflammation Integrated Security Life Sciences Medication

    Related ETFs - A few ETFs which own one or more of the above listed Glucagon Like Peptide 1 stocks.

    Symbol Grade Name Weight
    EDEN A iShares MSCI Denmark Capped ETF 23.21
    PPH C Market Vectors Pharmaceutical ETF 9.76
    IGTR C Innovator Gradient Tactical Rotation Strategy ETF 8.1
    PJIO D PGIM Jennison International Opportunities ETF 7.68
    AADR A WCM BNY Mellon Focused Growth ADR ETF 6.52
    View all Glucagon Like Peptide 1 ETFs...
    Compare ETFs
    Compare EDEN to IGTR Compare EDEN to PJIO Compare PPH to IGTR

        Glucagon Like Peptide 1 Stocks Recent News

        Date Stock Title
        May 6 NVO Investors Pile Into Amgen in Search of Next Obesity Drug Payout
        May 6 NVO Novo Nordisk doses first subject in Phase I trial of NLRP3 inhibitor
        May 6 NVO 'Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem
        May 4 NVO Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
        May 4 NVO Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
        May 3 NVO Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
        May 3 NVO Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript
        May 3 NVO Analyst unveils Amgen stock price target after weight-loss drug data
        May 3 NVO The FTC Cracks Down On Novo Nordisk's Ozempic
        May 3 NVO Weight-loss drug competition heats up. Is Wegovy in trouble?
        May 3 NVO Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
        May 3 NVO Amgen Knocks Novo Nordisk's Ozempic Stock Rally. Its Stock Is Flying.
        May 3 NVO FTC Seeks More Information on $16.5 Billion Novo-Catalent Deal
        May 3 NVO Catalent, Novo Nordisk receive FTC request for more information
        May 3 NVO US FTC seeks more information on Novo Nordisk parent-Catalent deal
        May 3 NVO UPDATE 2-US FTC seeks more information on Novo Nordisk parent-Catalent deal
        May 3 NVO Job Market Cools In April: Payrolls Miss Forecasts, Wages Rise Less Than Expected
        May 3 NVO How the CFOs of Eli Lilly and Novo Nordisk are coping with ‘unprecedented demand’ for weight-loss drugs
        May 3 NVO This Is a Huge Sigh of Relief for Novo Nordisk Investors
        May 3 NVO Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Diabetes Peptide Hormones Endocrine System Insulin Medicine Anti Diabetic Drugs Biopharmaceutical Chronic Disease Diabetes Care Gastrointestinal Growth Hormone Growth Hormone Therapy Haemophilia Hormone Therapy Hormones Implant Inflammation Integrated Security Life Sciences Medication
        Glucagon Like Peptide 1

        Glucagon-like peptide 1 (GLP-1) is a hormone that is produced in the gut and released in response to food intake. It stimulates insulin secretion, suppresses glucagon secretion, slows gastric emptying, and increases satiety. GLP-1 is a key regulator of glucose homeostasis and is used as a treatment for type 2 diabetes.

        Browse All Tags